University Hospital in Pilsen, Department of Nuclear Medicine - Immunoanalytic Laboratory, Czech Republic.
Biomark Med. 2013 Jun;7(3):403-6. doi: 10.2217/bmm.13.38.
The 40th annual Congress of the International Society of Oncology and Biomarkers took place in Jerusalem, Israel. The subtitle of this year's conference was: 'Innovations in oncological treatments and tumor markers'. Many issues on the potential use of markers were discussed, such as the potential use of markers for therapy response prediction in personalized medicine and for the proposal of algorithms for clinical practice use. A series of lectures was presented related to the discovery and preclinical and clinical validation of new biomarkers. The presentations were also split into keynote lectures, oral presentation in sessions and poster presentations. The conference was attended by approximately 186 participants and was attended by some of today's leading laboratory researchers in the field of oncology research. When comparing this conference with other meetings from previous years, it was evident that the biomarkers that are gaining in significance are DNA changes in association with the cancer process and epigenetic changes, which is seen to be methodically moving the field of immunoassays into molecular biology methods.
第 40 届国际肿瘤学和生物标志物学会年度大会在以色列耶路撒冷举行。今年会议的副标题是：“肿瘤学治疗和肿瘤标志物的创新”。会议讨论了许多关于标志物潜在用途的问题，例如标志物在个性化医学中预测治疗反应和提出用于临床实践的算法的潜在用途。还介绍了一系列与新生物标志物的发现以及临床前和临床验证相关的讲座。演讲分为主题演讲、会议口头报告和海报展示。会议约有 186 名参与者，参加者包括当今肿瘤学研究领域一些领先的实验室研究人员。将本次会议与前几年的其他会议进行比较时，显然，与癌症过程相关的 DNA 变化和表观遗传变化等具有重要意义的生物标志物正在将免疫分析领域系统地推向分子生物学方法。
